TrialsgrambetaRCTs are beautiful

FRAIL-AF

2024

Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation

In 1,330 frail elderly patients with atrial fibrillation stable on a vitamin K antagonist, switching to a DOAC increased major or clinically relevant bleeding compared with continuing the vitamin K antagonist.

Result

Efficacy: Composite of major or clinically relevant non-major bleedingHR 1.69 (95% CI 1.23-2.32)

Below 1 favours switching to a DOAC, above 1 favours continuing the vitamin K antagonist.

Event rates
Absolute difference
5.9 points
NNH
17

Absolute difference and NNH are derived from the event rates.

Also reported: Switching to a DOAC caused more bleeding than continuing a VKA, without offsetting thromboembolism reduction.

Original publication
Subtopic
DOAC switch
Design
Open-label superiority RCT with blinded adjudication, stopped early
Relevance
Important: one of several pillars.
Cited in
ESC 2024 AF
Source
Joosten LPT, et al. Circulation. 2024;149(4):279-289.doi 10.1161/CIRCULATIONAHA.123.066485

Discussion & critique

Applies to frail patients already stable on a VKA and does not argue against starting DOACs de novo. Challenged routine VKA-to-DOAC switching in frail elderly AF patients.

Discussed in podcasts